-
The company successfully launched an expanded manufacturing facility, increasing NexoBrid production capacity six-fold to meet projected global demand.
-
Revenues for 2025 were impacted by the US government shutdown, which delayed budget approval and the start of new development service contracts.
-
The Phase III VALUE trial for EscharEx in venous leg ulcers (VLU) is progressing as planned, with multiple clinical sites now active and enrolled.
-
The strategic expansion of the EscharEx program into diabetic foot ulcers (DFU) and pressure ulcers aims to capture the three major chronic wound indications.
-
Gross margin improvement in 2025 was driven by a more favorable revenue mix despite lower overall top-line results.
-
Management maintains operational flexibility and discipline in Israel despite the ongoing regional conflict, ensuring that clinical and commercial goals remain on track.
-
Industry credibility is enhanced through research collaborations with seven market-leading wound care companies, including a new partnership with B. Brown.
-
Revenue guidance of $24 million to $26 million for 2026 reflects regulatory approval of expanded manufacturing facilities and resumption of BARDA/DOW support.
-
The 2028 revenue target of $50 million to $55 million includes EscharEx’s first potential commercial offering, subject to regulatory approval.
-
Management expects to complete the EscharEx Phase III VALUE trial enrollment and conduct a scheduled interim evaluation by the end of 2026.
-
The Future Growth Strategy prioritizes national preparedness initiatives, including stockpiling and collaboration with military and emergency response systems.
-
The company plans to begin a Phase II study in diabetic foot ulcers and an investigator-initiated study in pressure ulcers during 2026.
-
The US government shutdown acted as the primary headwind in 2025, leading to a $7.0 million decrease in revenue compared to initial expectations.
-
A registered direct offering and underwriting exercise of $30.0 million strengthened the year-end cash balance sheet to $53.6 million.
-
R&D spending increased significantly to $14.0 million in 2025, reflecting the investment required for the EscharEx Phase III program.
-
The commercial release of the product from the new production site is subject to regulatory approvals expected in 2026.
-
Capacity has increased sixfold, but commercial output from the new site is expected in late 2026 subject to regulatory approvals.
-
Management noted that current demand in all regions exceeds current production capabilities, although they guided conservatively based on the expected settlement schedule.
